Metagenomi Therapeutics (MGX) Total Current Liabilities (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Total Current Liabilities data on file, last reported at $22.5 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $22.5 million, down 43.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.5 million (down 43.6% YoY), and the FY2025 annual result was $22.9 million, down 38.53% from the prior year.
• Total Current Liabilities slipped to $22.5 million in Q1 2026 per MGX's latest filing, from $22.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $70.7 million in Q1 2024 and troughed at $22.5 million in Q1 2026.
• A 4-year average of $42.4 million and a median of $38.6 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities slumped 45.82% in 2024, then tumbled 35.26% in 2025.
• A 4-year view of Total Current Liabilities shows it stood at $68.9 million in 2023, then tumbled by 45.82% to $37.3 million in 2024, then sank by 38.53% to $22.9 million in 2025, then decreased by 1.89% to $22.5 million in 2026.
• Business Quant data shows MGX's Total Current Liabilities at $22.5 million in Q1 2026, $22.9 million in Q4 2025, and $29.6 million in Q3 2025.